The impact of cancer on diabetes outcomes

Anne Beiter Arreskov, Maria Å Olsen, Sandra Sinius Pouplier, Volkert Siersma, Christen L Andersen, Søren Friis, Niels de Fine Olivarius, Anne Beiter Arreskov, Maria Å Olsen, Sandra Sinius Pouplier, Volkert Siersma, Christen L Andersen, Søren Friis, Niels de Fine Olivarius

Abstract

Background: Survival from many cancer types is steadily increasing, and as a result, a growing number of cancer patients will live with other chronic diseases, of which diabetes is one of the most prevalent. This study aims to describe the impact of cancer on health outcomes in patients with type 2 diabetes and to compare the effectiveness of a multifactorial intervention in diabetes patients with and without cancer.

Methods: The randomized controlled trial Diabetes Care in General Practice (DCGP) included 1381 patients newly diagnosed with type 2 diabetes. Patients were randomized to either six years of structured personal diabetes care or routine care. In a post hoc analysis, we followed patients for 19 years in Danish national registries for the occurrence of diabetes-related outcomes. We used Cox regression models to estimate hazard ratios for outcomes.

Results: At diagnosis 48 patients had cancer, and 243 patients were diagnosed with cancer during follow up. Patients with diabetes and cancer had excess all-cause mortality (HR 3.33; 95%CI 2.72-4.06), as well as an increased incidence of myocardial infarction (HR 1.76; 95%CI 1.29-2.39) and any diabetes-related outcome (HR 1.36; 95%CI 1.07-1.71). The intervention reduced the risk of both these endpoints in patients without cancer. Furthermore, there was no statistically significant difference in the effectiveness of the intervention among patients with and without cancer.

Conclusions: Diabetes patients with cancer had an increased risk of myocardial infarction and any diabetes-related outcome. The observed positive effect of structured personal diabetes care on clinical outcomes did not differ between patients with and without cancer. Attention to and prevention of diabetes complications in patients with both type 2 diabetes and cancer is warranted.

Trial registration: ClinicalTrials.gov NCT01074762 (February 24, 2010).

Keywords: All-cause mortality; Cancer; Diabetes care; Diabetes complication; Primary care; Randomized controlled trial; Type 2 diabetes.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The cumulative incidence of cancer during 20 years after diabetes diagnosis according to randomization arm. Kaplan–Meier curves. Solid line: structured personal care; dotted line: routine care

References

    1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014;15(1):23–34. doi: 10.1016/S1470-2045(13)70546-1.
    1. Pouwer F. Impact of cancer on use of glucose-lowering drug treatment in individuals with diabetes: potential mechanisms. Diabetologia. 2015;58(6):1378–1379. doi: 10.1007/s00125-015-3560-5.
    1. de Fine Olivarius N, Andreasen AH. Five-year all-cause mortality of 1323 newly diagnosed middle-aged and elderly diabetic patients. Data from the population-based study, diabetes care in general practice, Denmark. J Diabetes Complications. 1997;11(2):83–89. doi: 10.1016/S1056-8727(96)00096-7.
    1. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23(6):967–981. doi: 10.1007/s10552-012-9972-3.
    1. Williams GR, Mackenzie A, Magnuson A, Olin R, Chapman A, Mohile S, Allore H, Somerfield MR, Targia V, Extermann M, et al. Comorbidity in older adults with cancer. J Geriatric Oncol. 2015.
    1. Gallo M, Gentile L, Arvat E, Bertetto O, Clemente G. Diabetology and oncology meet in a network model: union is strength. Acta Diabetol. 2016;53(4):515–524. doi: 10.1007/s00592-016-0839-z.
    1. Psarakis HM. Clinical Chalenges in caring for patients with diabetes and Cancer. Diabetes Spectrum. 2006;19(3):157–162. doi: 10.2337/diaspect.19.3.157.
    1. Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Wolff AC, Carducci MA, Earle CC. Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol. 2013;31(9):1140. doi: 10.1200/JCO.2012.43.0272.
    1. Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101(8):1712–1719. doi: 10.1002/cncr.20560.
    1. Sabatino SA, Coates RJ, Uhler RJ, Pollack LA, Alley LG, Zauderer LJ. Provider counseling about health behaviors among cancer survivors in the United States. J Clin Oncol. 2007;25(15):2100. doi: 10.1200/JCO.2006.06.6340.
    1. Yao N, Camacho FT, Chukmaitov AS, Fleming ST, Anderson RT. Diabetes management before and after cancer diagnosis: missed opportunity. Ann Transl Med. 2015;3(5):72.
    1. Ranc K, Jorgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia. 2014;57(5):927–934. doi: 10.1007/s00125-014-3186-z.
    1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. Jama. 2008;300(23):2754–2764. doi: 10.1001/jama.2008.824.
    1. Zhao XB, Ren GS. Diabetes mellitus and prognosis in women with breast cancer: a systematic review and meta-analysis. Medicine. 2016;95(49):e5602. doi: 10.1097/MD.0000000000005602.
    1. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. doi: 10.2147/CLEP.S47150.
    1. Hansen LJ, Siersma V, Beck-Nielsen H, de Fine Olivarius N. Structured personal care of type 2 diabetes: a 19 year follow-up of the study diabetes Care in General Practice (DCGP) Diabetologia. 2013;56(6):1243–1253. doi: 10.1007/s00125-013-2893-1.
    1. Pouplier S, Olsen MA, Willadsen TG, Sandholdt H, Siersma V, Andersen CL, Olivarius NF. The development of multimorbidity during 16 years after diagnosis of type 2 diabetes. J Comorb. 2018;8(1):2235042x18801658. doi: 10.1177/2235042X18801658.
    1. Larsen JR, Siersma VD, Davidsen AS, Waldorff FB, Reventlow S, de Fine Olivarius N. The excess mortality of patients with diabetes and concurrent psychiatric illness is markedly reduced by structured personal diabetes care: a 19-year follow up of the randomized controlled study diabetes Care in General Practice (DCGP) Gen Hosp Psychiatry. 2016;38:42–52. doi: 10.1016/j.genhosppsych.2015.10.001.
    1. Krag MO, Hasselbalch L, Siersma V, Nielsen AB, Reventlow S, Malterud K, de Fine Olivarius N. The impact of gender on the long-term morbidity and mortality of patients with type 2 diabetes receiving structured personal care: a 13 year follow-up study. Diabetologia. 2016;59(2):275–285. doi: 10.1007/s00125-015-3804-4.
    1. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish civil registration system. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441–449.
    1. Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26–29. doi: 10.1177/1403494811399958.
    1. Gjerstorff ML. The Danish cancer registry. Scand J Public Health. 2011;39(7 Suppl):42–45. doi: 10.1177/1403494810393562.
    1. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl):30–33. doi: 10.1177/1403494811401482.
    1. Kalbfleisch JDPR. The statistical analysis of failure time data. 2. NewYork: Wiley; 2002.
    1. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619–1632. doi: 10.1007/s00125-012-2526-0.
    1. Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K. Mortality causes in cancer patients with type 2 diabetes mellitus. Eur J Cancer Prev. 2012;21(3):300–306. doi: 10.1097/CEJ.0b013e32834c9cd9.
    1. Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol. 2017;14(2):85–99. doi: 10.1038/nrclinonc.2016.120.
    1. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114. doi: 10.1161/CIRCULATIONAHA.115.020406.
    1. Cameron AC, Touyz RM, Lang NN. Vascular complications of Cancer chemotherapy. Can J Cardiol. 2016;32(7):852–862. doi: 10.1016/j.cjca.2015.12.023.
    1. Hua F, Yu JJ, Hu ZW. Diabetes and cancer, common threads and missing links. Cancer Lett. 2016;374(1):54–61. doi: 10.1016/j.canlet.2016.02.006.
    1. Morris RL, Sanders C, Kennedy AP, Rogers A. Shifting priorities in multimorbidity: a longitudinal qualitative study of patient's prioritization of multiple conditions. Chronic Illn. 2011;7(2):147–161. doi: 10.1177/1742395310393365.
    1. Kerr EA, Heisler M, Krein SL, Kabeto M, Langa KM, Weir D, Piette JD. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients’ treatment priorities and self-management? J Gen Intern Med. 2007;22(12):1635–1640. doi: 10.1007/s11606-007-0313-2.
    1. Hershey DS, Tipton J, Given B, Davis E. Perceived impact of cancer treatment on diabetes self-management. Diabetes Educ. 2012;38(6):779–790. doi: 10.1177/0145721712458835.
    1. Calip GS, Elmore JG, Boudreau DM. Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors. Breast Cancer Res Treat. 2017;161(1):161–172. doi: 10.1007/s10549-016-4043-1.
    1. Zanders MM, Haak HR, Van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA. Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia. 2015;58(5):951–960. doi: 10.1007/s00125-015-3497-8.
    1. Shin JY, Shim HY, Jun JK. Comparison of diabetes management status between cancer survivors and the general population: results from a Korean population-based survey. PLoS One. 2014;9(10):e110412. doi: 10.1371/journal.pone.0110412.
    1. Chiao EY, Nambi PV, Naik AD. The impact of diabetes process and outcome quality measures on overall survival in patients with co-morbid colorectal cancer. J Cancer Surviv. 2010;4(4):381–387. doi: 10.1007/s11764-010-0141-y.
    1. Keating LN, Zaslavsky MA, Herrinton JL, Selby VJ, Wolf ER, Ayanian ZJ. Quality of diabetes care among cancer survivors with diabetes. Med Care. 2007;45(9):869–875. doi: 10.1097/MLR.0b013e31806728e9.
    1. Policardo L, Barchielli A, Seghieri G, Francesconi P. Does the hospitalization after a cancer diagnosis modify adherence to process indicators of diabetes care quality? Acta Diabetol. 2016;53(6):1009–1014. doi: 10.1007/s00592-016-0898-1.
    1. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447–1451. doi: 10.1200/JCO.2003.03.060.
    1. Bayliss EA, Blatchford PJ, Newcomer SR, Steiner JF, Fairclough DL. The effect of incident cancer, depression and pulmonary disease exacerbations on type 2 diabetes control. J Gen Intern Med. 2011;26(6):575–581. doi: 10.1007/s11606-010-1600-x.
    1. Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54(9):2263–2271. doi: 10.1007/s00125-011-2242-1.
    1. Geier AS, Wellmann J, Wellmann I, Kajuter H, Heidinger O, Hempel G, Hense HW. Cancer detection rates following enrolment in a disease management programme for type 2 diabetes. Diabetologia. 2013;56(9):1944–1948. doi: 10.1007/s00125-013-2947-4.
    1. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer registry--history, content, quality and use. Dan Med Bull. 1997;44(5):535–539.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe